AILERON THERAPEUTICS INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;

           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On June 15, 2022, the Board of Directors of Aileron Therapeutics, Inc. (the "Company") appointed Susan L. Drexler, a consultant at Danforth Advisors, LLC ("Danforth"), as interim chief financial officer, effective as of June 16, 2022. In connection with her appointment, Ms. Drexler will serve as the Company's principal financial officer and principal accounting officer.

Ms. Drexler will provide interim chief financial officer services pursuant to a consulting agreement to which the Company is a party with Danforth. Under the consulting agreement, the Company will pay Danforth an agreed upon hourly rate for Ms. Drexler's services and will reimburse Danforth for expenses. The consulting agreement may be terminated by the Company or Danforth with cause, upon 30 days written notice, and without cause, upon 60 days written notice.

Ms. Drexler, age 52, has extensive experience as a chief financial officer, with over 25 years of experience with development and commercial stage life science companies. Since January 2022, Ms. Drexler has served as a consultant at Danforth, a provider of strategic and operational finance and accounting for life science companies. Ms. Drexler has served as interim chief financial officer of Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, since April 2022. Previously, Ms. Drexler served as chief financial officer of Harmony Biosciences Holdings, Inc., a pharmaceutical company, from October 2019 through March 2021. Ms. Drexler also served as acting chief financial officer and vice president, business development of Ocugen, Inc., a biotechnology company, from April 2018 through June 2019 and as senior director, strategy and business development and then vice president, business development and market intelligence at AmerisourceBergen Drug Corporation, a pharmaceutical sourcing and distribution services company, from August 2015 through November 2017. Ms. Drexler previously served as director, corporate finance of Shire plc from 2007 through 2015. She received a B.S. in Accounting from Albright College and an MBA in Finance from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh.

Ms. Drexler has no family relationships with any of the executive officers or directors of the Company. There are no arrangements or understandings between Ms. Drexler and any other person pursuant to which he was elected as an officer of the Company.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 15, 2022, the Company held its Annual Meeting to consider and vote upon the matters listed below. The following is a summary of the matters voted on at that meeting.

    (a)  The stockholders of the Company elected William McKee and Nolan Sigal as
         Class II directors for a three-year term expiring at the annual meeting
         of stockholders to be held in 2025. The results of the stockholders' vote
         with respect to such matter were as follows:



                                              Broker
Name                  For       Withheld    Non-Votes
William T. McKee   44,487,407   2,277,523   18,414,250
Nolan H. Sigal     44,363,743   2,402,187   18,414,250



    (b)  The stockholders of the Company approved an amendment to the Company's
         Amended and Restated Certificate of Incorporation to effect a reverse
         stock split at a ratio of not less than 1-for-5 and not greater than
         1-for-25, with the exact ratio to be set within that range at the
         discretion of the Company's board of directors prior to December 31, 2022
         without further approval or authorization of the Company's stockholders,
         in its sole discretion, and, in connection therewith, to decrease the
         number of authorized shares of our common stock on a basis proportional
         to the reverse stock split ratio. The results of the stockholders' vote
         with respect to such matter were as follows:



   For        Against     Abstain
57,576,087   2,252,608   5,350,485

--------------------------------------------------------------------------------

    (c)  The stockholders of the Company approved an amendment to the Company's
         Amended and Restated Certificate of Incorporation to set the number of
         authorized shares of common stock at a number determined by calculating
         the product of 300,000,000 multiplied by three times the reverse stock
         split ratio, subject to the board's implementation of the reverse stock
         split. The results of the stockholders' vote with respect to such matter
         were as follows:



   For        Against      Abstain
49,080,551   10,733,263   5,365,366



    (d)  The stockholders of the Company ratified the appointment of
         PricewaterhouseCoopers LLP as the Company's independent registered public
         accounting firm for the fiscal year ending December 31, 2022. The results
         of the stockholders' vote with respect to such matter were as follows:



   For       Against   Abstain
64,545,310   509,725   124,145

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses